Strategic partnerships Nabla Bio actively collaborates with major pharma players including AstraZeneca, Bristol Myers Squibb, and Takeda, presenting ready-made BD opportunities for co-development, licensing, or expanded pipeline programs.

Generative protein design The company specializes in AI-driven and wet-lab tech to design developable, selective, functional drugs for previously undruggable targets, creating attractive targets for pharma partners seeking novel modalities.

Significant funding momentum Recent Series A funding of 26M plus earlier seed rounds demonstrates strong investor validation and financial appetite, suggesting capacity for expanded collaboration and scalable pilot projects.

Revenue and scope With reported revenue in the low tens of millions and a high-impact collaboration model, Nabla Bio offers a pathway for risk-sharing partnerships, milestone-driven deals, and potential upfront payments tied to target validation.

Talent and IP leverage A focused team in Cambridge with expertise in machine learning and synthetic biology positions Nabla Bio to accelerate joint programs, enabling accelerated hit-to-lead candidates and leveraging proprietary tech for competitive advantage.